کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
9313137 1250469 2005 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The current role of chemotherapy in metastatic hormone-refractory prostate cancer
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیماری‌های کلیوی
پیش نمایش صفحه اول مقاله
The current role of chemotherapy in metastatic hormone-refractory prostate cancer
چکیده انگلیسی
Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urology - Volume 65, Issue 5, Supplement, May 2005, Pages 3-7
نویسندگان
,